Cargando…

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment

(1) This study aimed to investigate whether baseline clinical and Positron Emission Tomography/Computed Tomography (bPET)-derived parameters could help predicting early response to the first two cycles of chemotherapy (Deauville Score at interim PET, DS at iPET) in patients with classical Hodgkin ly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Triumbari, Elizabeth Katherine Anna, Morland, David, Cuccaro, Annarosa, Maiolo, Elena, Hohaus, Stefan, Annunziata, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600607/ https://www.ncbi.nlm.nih.gov/pubmed/36292014 http://dx.doi.org/10.3390/diagnostics12102325

Ejemplares similares

Healthy Organs Uptake on Baseline (18)F-FDG PET/CT as an Alternative to Total Metabolic Tumor Volume to Predict Event-Free Survival in Classical Hodgkin's Lymphoma
por: Morland, David, et al.
Publicado: (2022)

Baseline (18)F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2023)

PD‐L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2022)

Prognostic Factors in Hodgkin Lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2014)

Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)

CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2016)

Severe CMV Infection after Chemo-Immunotherapy with Dose-Reduced Bendamustine and Rituximab in a Mantle Cell Lymphoma Old Patient
por: Magliano, Gabriele, et al.
Publicado: (2021)

Radiomics in Oncological PET Imaging: A Systematic Review—Part 1, Supradiaphragmatic Cancers
por: Morland, David, et al.
Publicado: (2022)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
por: André, M., et al.
Publicado: (2011)

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
por: Hohaus, Stefan, et al.
Publicado: (2020)

Radiomics in Oncological PET Imaging: A Systematic Review—Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers
por: Morland, David, et al.
Publicado: (2022)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
por: Al-Ibraheem, Akram, et al.
Publicado: (2022)

Interobserver variability in interim PET assessment in Hodgkin lymphoma—reasons and solutions
por: Georgi, Thomas W., et al.
Publicado: (2023)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization
por: Hohaus, Stefan, et al.
Publicado: (2018)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients
por: Ferretti, Elisa, et al.
Publicado: (2017)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009)

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial
por: Georgi, Thomas W., et al.
Publicado: (2020)

Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
por: Plattel, Wouter J., et al.
Publicado: (2020)

Vitamin D deficiency and supplementation in patients with aggressive B‐cell lymphomas treated with immunochemotherapy
por: Hohaus, Stefan, et al.
Publicado: (2017)

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study
por: Durmo, Rexhep, et al.
Publicado: (2022)

Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients
por: Furth, Christian, et al.
Publicado: (2013)

Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma
por: Liao, Cheng-Cheng, et al.
Publicado: (2017)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Pediatric Hodgkin Lymphoma: Predictive value of interim (18)F-FDG PET/CT in therapy response assessment
por: Ferrari, Cristina, et al.
Publicado: (2017)

Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden
por: Leccisotti, Lucia, et al.
Publicado: (2022)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin’s and aggressive non-hodgkin’s lymphomas
por: Ganeshan, B., et al.
Publicado: (2016)

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
por: Morland, David, et al.
Publicado: (2023)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

Epstein-Barr Virus (EBV)-Associated Haemophagocytic Syndrome
por: Torti, Lorenza, et al.
Publicado: (2012)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_21gf3p8d581v6rmoij87bkgj4k